Blood

Chronic myeloid leukemia

ORPHA:521 ↗Gene BCR Gene ABL1 Gene RUNX1

Search all Chronic myeloid leukemia trialsAlert me when a trial opens

148

studies recruiting now

as of 7 Sept 2026

1,810

studies registered in total

as of 7 Sept 2026

countries with a recruiting site

as of 7 Sept 2026

24 Apr 2026

most recent study posted

among recruiting studies

Recruiting trials

RecruitingPhase 1NCT06904066

Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

Sponsor National Cancer Institute (NCI)Where United States (1 site)Studying aldesleukin, cyclophosphamideUpdated 4 Sept 2026

See details

RecruitingPhase 2NCT03383575

Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome

Sponsor M.D. Anderson Cancer CenterWhere United States (3 sites)Studying Azacitidine, EnasidenibUpdated 4 Sept 2026

See details

RecruitingPhase 1 / Phase 2NCT04588922

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

Sponsor Sellas Life Sciences GroupWhere United States, China (32 sites)Studying SLS009, venetoclaxUpdated 3 Sept 2026

See details

RecruitingNCT07549516

A Study on the Tolerability, Safety and Effectiveness of Asciminib in Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in the Chronic Phase in Germany

Sponsor Novartis PharmaceuticalsWhere Germany (65 sites)Updated 3 Sept 2026

See details

RecruitingPhase 3NCT03459534

A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs

Sponsor Il-Yang Pharm. Co., Ltd.Where Russia, South Korea, Turkey (Türkiye) +1 (18 sites)Studying Radotinib HClUpdated 3 Sept 2026

See details

Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.

See all 148 recruiting studies

Where recruiting studies are running

Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.

China Germany Russia South Korea Turkey (Türkiye)Ukraine United States

Keep watching

Get an email when a new Chronic myeloid leukemia study opens.

One email a day at most. Unsubscribe with one click.

Used only for these alerts. Privacy.

Support

Patient organisations

We do not yet list a dedicated organisation for this condition. The directories below are the best route.

NORD ↗GARD ↗Orphanet ORPHA:521 ↗

About Chronic myeloid leukemia

RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations, and the genes involved (BCR, ABL1, RUNX1).

Orphanet expert page ↗GARD (NIH) ↗

Treatments being studied

14 approved treatments and 51 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.

Approved: Imatinib Mesylate (Gleevec)Approved: Omacetaxine Mepesuccinate (Synribo)Approved: Bosutinib Monohydrate (Bosulif)Approved: Hydroxyurea (Droxia)Approved: Interferon Alfa-N1 (Well-feron)Approved: Dasatinib (Dasatinib accord healthcare)Approved: NilotinibApproved: Nilotinib Hydrochloride Monohydrate (Tasigna)Approved: Busulfan (Busilvex)Approved: Asciminib Hydrochloride (Scemblix)Approved: Ponatinib Hydrochloride (Iclusig)Approved: AsciminibApproved: Dasatinib Anhydrous (Dasatinib accord)Approved: Imatinib

Phase 3Olverembatinib

Phase 3Cytarabine (Alexan)

Phase 3Cyclophosphamide (Cyclophosphamide)

Phase 3Sargramostim (Leukine)

Phase 3Interferon Alfa

Phase 3Bosutinib

Phase 3Peginterferon Alfa-2a (Pegasys)

Phase 3Ponatinib (Iclusig)

+ 43 more in development

Related conditions

Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).